AMSTERDAM — For patients with diffuse cutaneous systemic sclerosis, an autoimmune disease for which there are few treatment options, lenabasum (JBT-101, Corbus Pharmaceuticals) shows potential, new ...
Please provide your email address to receive an email when new articles are posted on . Patients showed no difference in skin fibrosis whether they were given low-dose oral glucocorticoids or not. One ...
Scleroderma, or systemic sclerosis refers to a disorder in which the skin and connective tissues of the body start to thicken and harden because of the overproduction of a protein called collagen.
The investigational therapy will be used in Kyverna's KYSA-5 Phase 1/2 open-label, multicenter study to evaluate KYV-101 in adult patients with diffuse cutaneous systemic sclerosis (scleroderma) This ...
Although less common than other subtypes of systemic sclerosis (SSc), systemic sclerosis sine scleroderma (ssSSc) makes up more than 8% of SSc cases and "should not be neglected," according to a new ...
Q: My daughter, who is 14-years-old, was diagnosed with localized scleroderma about three years ago, and I am finding out that not much is known on this disease. Could you tell be about it? Does it ...
Suggested Citation: "4 Scleroderma." National Academies of Sciences, Engineering, and Medicine. 2022. Selected Immune Disorders and Disability. Washington, DC: The ...
Most people with scleroderma have autoantibodies. Several scleroderma-specific antibodies have been identified. These can help with diagnosis and give insight into the type of disease you may ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results